Quantum Genomics SA represents values of innovation, dedication, and excellence in the field of cardiovascular diseases. The company's corporate philosophy revolves around their commitment to developing breakthrough therapies for patients suffering from high blood pressure and heart failure. Quantum Genomics SA aims to provide effective solutions through their cutting-edge research and pharmaceutical advancements. With a focus on addressing unmet medical needs, they strive to improve the quality of life for individuals worldwide. By combining scientific expertise and a patient-centric approach, Quantum Genomics SA is dedicated to making a significant impact on cardiovascular healthcare.

Quantum Genomics SA is primarily present in multiple countries and regions. The company has a global presence with a significant focus on key markets such as the United States, Europe, and Asia. Quantum Genomics SA operates in various countries within these regions, including France, the United Kingdom, Germany, Belgium, Switzerland, China, Japan, and South Korea. With its expanding international footprint, Quantum Genomics SA aims to reach a wide range of markets and capitalize on the global potential for its innovative pharmaceutical solutions.

Quantum Genomics SA, a leading biopharmaceutical company, has achieved several significant milestones. The company successfully completed Phase IIb clinical trials for its flagship drug, Firibastat, demonstrating its effectiveness in treating hypertension and heart failure. Quantum Genomics also secured strategic partnerships with renowned pharmaceutical companies, accelerating the drug's development and expanding its market reach. Furthermore, the company obtained regulatory approvals in Europe and the United States, paving the way for commercialization. Quantum Genomics SA's dedication to innovation and clinical excellence has positioned it as a key player in the field of cardiovascular diseases, with promising prospects for future growth and success.

Quantum Genomics SA is a leading biopharmaceutical company specializing in the development of innovative treatments for cardiovascular diseases. Founded in 2005, Quantum Genomics has made significant strides in the field of hypertension and heart failure research. With a focus on pioneering new therapeutic approaches, the company has developed QGC001, a first-in-class medication targeting brain aminopeptidase A (APA). By leveraging its expertise in molecular and cellular pharmacology, Quantum Genomics aims to revolutionize cardiovascular treatments and improve patient outcomes. With a dedicated team and a strong pipeline, Quantum Genomics SA continues to make advancements in its pursuit of breakthrough solutions for cardiovascular health.

The main competitors of Quantum Genomics SA in the market include pharmaceutical companies like Novartis AG, Pfizer Inc., and AstraZeneca PLC. These companies actively participate in the development and commercialization of cardiovascular and central nervous system (CNS) medicines, similar to Quantum Genomics SA. With its innovative approach in developing drugs targeting hypertension and heart failure, Quantum Genomics SA competes with established pharmaceutical players to expand its market presence. By leveraging its distinctive technology and scientific expertise, Quantum Genomics SA aims to gain a competitive edge and capture a significant market share in the cardiovascular and CNS therapeutic areas.

Quantum Genomics SA is primarily active in the pharmaceutical industry.

The business model of Quantum Genomics SA is focused on developing treatments for cardiovascular diseases and hypertension. By leveraging its unique expertise in the field of brain aminopeptidases and its understanding of their role in cardiovascular diseases, Quantum Genomics aims to create innovative and effective therapies. The company's approach involves developing drugs that target specific brain aminopeptidases, inhibiting their activity and ultimately reducing blood pressure. Through its research and development efforts, Quantum Genomics aims to provide patients with improved treatment options and contribute to the advancement of cardiovascular medicine.

Quantum Genomics P/E-luku on 0,01.

Quantum Genomics KUV on 0,02.

AlleAktien Laatuscore Quantum Genomics on 4/10.

odotettu Quantum Genomics liikevaihto on 138,69 milj. EUR.

odotettu Quantum Genomics voitto on 302,64 milj. EUR.

Quantum Genomics SA is a French biotechnology company specializing in the development of new therapies for hypertension and heart failure. The company uses its unique technology platform to develop drugs that interact with the brain in a unique way. Its business model is based on the invention, development, production, and marketing of innovative, novel, and patented medications for the treatment of cardiometabolic diseases. The company focuses on developing its capabilities in research, development, and commercial activities. It aims to sell its innovative technologies and products worldwide through collaboration with local and international leading research centers in cardiometabolic research. With a team of experienced researchers and experts in the pharmaceutical industry, Quantum Genomics is able to bring its products to market quickly and efficiently. The company continuously invests in research and development to improve its technologies and develop new products. It aims to maintain its competitive advantage through the protection of its intellectual property rights and collaboration with other pharmaceutical companies and research organizations. One of Quantum Genomics’ core areas is the research and development of new therapies for hypertension and heart failure. The company has conducted extensive clinical research and developed several drug candidates that interact with the brain in innovative ways, promoting better blood pressure and cardiovascular health. The company has already achieved a significant milestone by successfully gaining approval for its development candidates for clinical trials. Quantum Genomics also has partnerships with other pharmaceutical companies to maximize the potential of its technologies and increase its presence in the market. Through strategic partnerships and licensing agreements, Quantum Genomics aims to market its technology platform worldwide. In addition to its work in cardiometabolic research, Quantum Genomics also has an extensive pipeline of drug candidates for other diseases, such as chronic pain and other psychiatric disorders. The company has already achieved important milestones and established its innovative products in the market. It has strong growth potential and is on a positive path to becoming a key player in the pharmaceutical and biotechnology industry. Overall, Quantum Genomics SA's business model is focused on the development and marketing of innovative therapies for cardiometabolic diseases. The company aims to protect its innovation capabilities and intellectual property rights to strengthen its position in the market and achieve a leadership position in the industry. Quantum Genomics is committed to increasing its presence both in France and internationally and developing partnerships with other pharmaceutical companies to market its technology platform worldwide.

Quantum Genomics maksaa osinkoa 0 EUR, joka jaetaan erässä vuoden aikana.

Osinkoa ei voida tällä hetkellä laskea Quantum Genomics:lle tai yhtiö ei maksa osinkoa.

Quantum Genomics:n ISIN on FR0011648971.

Quantum Genomics:n WKN on A1XAEB.

Quantum Genomics:n tunnus on ALQGC.PA.

Viimeisen 12 kuukauden aikana Quantum Genomics maksoi osinkoa edestä. Tämä vastaa noin osinkotuottoa. Seuraavan 12 kuukauden aikana Quantum Genomics maksanee ennusteiden mukaan 0 EUR osingon.

Quantum Genomics:n tämänhetkinen osinkotuotto on .

Quantum Genomics maksaa osinkoa neljännesvuosittain. Osingot jaetaan kuukausina .

Quantum Genomics maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Seuraavalle 12 kuukaudelle odotetaan 0 EUR suuruisia osinkoja. Tämä vastaa 0 % osinkotuottoa.

Quantum Genomics kuuluu sektoriin 'Terveys'.

Saadaksesi viimeisimmän Quantum Genomics osingon 18.11.2024, jonka suuruus on 0 EUR, sinun oli oltava omistanut osakkeen ennen ex-päivää, joka oli 18.11.2024.

Viimeisin osinko maksettiin 18.11.2024.

Vuonna 2023 Quantum Genomics maksoi 0 EUR osinkoina.

Quantum Genomics:n osingot maksetaan EURssa.